We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 07, 2021

Delayed BCG Immunotherapy After Transurethral Resection of Bladder Cancer Is Associated With Adverse Survival Outcomes

World Journal of Urology


Additional Info

Disclosure statements are available on the authors' profiles:

World Journal of Urology
Delaying BCG Immunotherapy Onset After Transurethral Resection of Non-Muscle-Invasive Bladder Cancer Is Associated With Adverse Survival Outcomes
World J Urol 2020 Nov 23;[EPub Ahead of Print], W Krajewski, M Moschini, J Chorbińska, Ł Nowak, S Poletajew, A Tukiendorf, L Afferi, JY Teoh, T Muilwijk, S Joniau, A Tafuri, A Antonelli, F Cianflone, A Mari, E Di Trapani, K Hendricksen, M Alvarez-Maestro, A Rodríguez-Serrano, G Simone, S Zamboni, C Simeone, MC Marconi, R Mastroianni, G Ploussard, E Laukhtina, K Tully, A Kołodziej, J Krajewska, R Piszczek, E Xylinas, R Zdrojowy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading